|
|
|
| home > ebr > current issue |
|
|
 PUBLICATIONS |
European Biopharmaceutical Review |
|
|
|
|
|
 |
| |
|
|
|
Editor’s Letter
EBR's Editor, Dr Deborah O'Neil, details all the innovations touched upon in this issue and how the majority can enhance cancer treatment.
|
|
|
|
|
Label-Free Biosensing
Protein Progression
Following a significant increase in quality, peptide and protein microarrays now have the potential to offer brand new opportunities in pharmaceutical and proteomics R&D, claims Güenther Proll at Biametrics.
|
|
|
|
Process-Specific Versus Generic Host Cell Protein Impurity Assays
Biologics Process Analysis
Given the rise in therapeutic antibody production, it has become more important than ever to address issues associated with host cell proteins, as detailed by Ken Hoffman, Eric Bishop, Dr Alla Zilberman, and Dr Jared Isaac at Cygnus Technologies.
|
|
|
|
Generating High-Quality Protein Reagents from Eukaryotic Cells
Cell Culture Considerations
Both Escherichia coli and eukaryotic systems have their pros and cons, yet the former is selected more often due to speed and cost implications. Dr Mark Abbott at Peak Proteins discusses the factors to be considered.
|
|
|
|
Improving Pharmacokinetic Assays in a Regulatory Bioanalysis Setting
Applying Affimers
Dr Amanda Nicholl at Avacta Life Sciences expresses the fundamentality of pharmacokinetic assay results in the phases of drug development and how to increase the effectiveness and efficacy of antibody drug development.
|
|
|
|
Peptides in Plasma
Determining Peptides
Determination in plasma can be particularly complicated, especially when dealing with peptides, but Professor Hermann Mascher at pharm-analyt believes it is still a route worth taking.
|
|
|
|
|
|
Purifying Oligonucleotides
Produce Potential
Dr Cecilia Unoson and Dr Lars Haneskog at Bio-Works Technologies delve into whether the necessary yield and purity of oligonucleotides can be attained through anion exchange chromatography.
|
|
|
|
|
|
Advanced Therapies
Rising to the Challenge
Dr Fiona Thistlethwaite at The Christie Hospital and Dr Ian Thomas at Aptus Clinical explore the challenges of bringing advanced therapy medicinal products to market and the considerations that must be made.
|
|
|
|
Tissue-Agnostic Approvals
A New Oncology Era
New advances in tumourigenesis have laid the foundations for a molecular marker that assists in defining and treating cancers, explains Dr Terese Johansson at NDA Group.
|
|
|
|
Cancer Therapy Innovations
Oncological Advances
Dr Kathryn D Bungartz at N-of-One provides an overview of how advanced imaging techniques and improved preventative measures have transformed the world of cancer innovation.
|
|
|
|
In Vitro Bioassays
Candidate Selection
The cancer immunotherapies field has made notable progress in its clinical application, and combination therapies may be a viable force to drive these advancements further, suggest Thibault Janss and Sofie Pattijn at ImmunXperts.
|
|
|
|
Diafiltration of Antibody-Drug Conjugates
Novel TFF Capsule Evaluation
The teams at Sanofi and Merck Group demonstrate the advantages of antibody-drug conjugates as cancer chemotherapeutics.
|
|
|
|
|
|
Electroceutical Therapy for Chronic Pain
Effective Electroceuticals
Dr Sree Koneru at BioElectronic Corporation and Dr Kenneth McLeod at the State University of New York in Binghamton, outline the benefits of electroceutical treatments for many neurological disorders and compare this to the widely recognised central sensitisation.
|
|
|
|
Benefits of Bioelectronic Medicine
Theory to Game Changer
As the use of bioelectronics is on the rise following the adoption of electric devices as main treatment options, Pascaline Vancraeyenest at Healtech identifies how the reliance on drugs is potentially becoming limited.
|
|
|
|
The Future of Bioelectronic Medicine
Targeted Technology
Dr Deepak B Thimiri Govinda Raj, Prasanna Subramaniam, Dr Sri Saran Venkatachalam, and Dr Dinh-Toi Chu at Envirotransgene Biosolutions examine why bioelectronic medicine is regarded as a disruptive technology in healthcare.
|
|
|
|
|
|
In Brief
GOAL!
Following this year's approval of the first RNA interference-based human therapy, EBR's Industry Advisor, Emile Bellott, takes a look at its new role as a game-changer within the biopharma industry.
|
|
|
|
|
|
 |
|
|
 |
News and Press Releases |
 |
BioIVT Introduces New Quality Management System to Maintain Highest Quality Biospecimens and Drug Development Research Services
BioIVT, a leading provider of research models and services for drug and diagnostic development, today announced that it is introducing a new internal cloud-based Quality Management System (QMS), Master Control. This new standardized, ISO compliant QMS will help BioIVT manage documentation, auditing, supplier and customer accounts, and risk across all locations. It will consolidate and replace a variety of computer- and paper-based document control systems located at existing and newly-acquired BioIVT sites in the US, Europe and Asia.
More info >> |
|
 |
White Papers |
 |
|
Unmet Medical Needs? Impacted by unmet Life Sciences Staffing Needs?
Clinical Professionals
Whilst the majority of Clinical Professionals clients are working to discover and develop innovative, cost effective medicines that address unmet medical needs they are not impacting the unmet needs of training and developing new recruits into the pharma industry. The impact is highlighted within entry level Clinical Trial Administrators and Clinical Research Associates (CTA/CRA). In the past the Pharmaceutical industry had highly developed training programs for these sought after candidates. As the use of outsourcing models and CRO’s has increased and fewer Pharma businesses embark on their own R&D a substantial gap is developing in newly trained Life Science graduates entering the market to commence a career within R&D. As further financial cuts are made within R&D spend this already dire situation continues to escalate.
More info >> |
|
 |
Industry Events |
 |
4th Annual Genome Editing Congress
8-9 November 2018, London, UK
Oxford Global is proud to present its 4thAnnual Genome Editing Congress taking place on 8-9 November 2018 in London. As
part of our Genomics and Synthetic Biology UK series, our congress will
bring together Over 600 delegates representing internationally renowned
research & academic institutions, clinical research institutions and
pharmaceutical companies.
More info >> |
|
|
